ECSP099706A - NEW DERIVATIVES OF N- (8-HETEROARILTETRAHIDRONAFTALEN-2YL) AND N- (5-HETEROARILCROMAN-3-IL) CARBOXAMIDE FOR THE TREATMENT OF PAIN - Google Patents

NEW DERIVATIVES OF N- (8-HETEROARILTETRAHIDRONAFTALEN-2YL) AND N- (5-HETEROARILCROMAN-3-IL) CARBOXAMIDE FOR THE TREATMENT OF PAIN

Info

Publication number
ECSP099706A
ECSP099706A EC2009009706A ECSP099706A ECSP099706A EC SP099706 A ECSP099706 A EC SP099706A EC 2009009706 A EC2009009706 A EC 2009009706A EC SP099706 A ECSP099706 A EC SP099706A EC SP099706 A ECSP099706 A EC SP099706A
Authority
EC
Ecuador
Prior art keywords
heteroariltetrahidronaftalen
heteroarilcroman
carboxamide
pain
treatment
Prior art date
Application number
EC2009009706A
Other languages
Spanish (es)
Inventor
Yevgeni Besidski
Inger Kers
Martin Nyloef
Karin Skogholm
Lars Sandberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39876087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP099706A publication Critical patent/ECSP099706A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos compuestos de fórmula (I) y a una composición farmacéutica que contiene dichos compuestos y al uso de dichos compuestos en terapia. La presente invención se refiere además a los procesos para la preparación de dichos compuestos y a nuevos intermedios útiles en la preparación de estos.The present invention relates to new compounds of formula (I) and a pharmaceutical composition containing said compounds and the use of said compounds in therapy. The present invention further relates to the processes for the preparation of said compounds and to new intermediates useful in the preparation of these.

EC2009009706A 2007-04-23 2009-10-29 NEW DERIVATIVES OF N- (8-HETEROARILTETRAHIDRONAFTALEN-2YL) AND N- (5-HETEROARILCROMAN-3-IL) CARBOXAMIDE FOR THE TREATMENT OF PAIN ECSP099706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91331207P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
ECSP099706A true ECSP099706A (en) 2009-11-30

Family

ID=39876087

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009706A ECSP099706A (en) 2007-04-23 2009-10-29 NEW DERIVATIVES OF N- (8-HETEROARILTETRAHIDRONAFTALEN-2YL) AND N- (5-HETEROARILCROMAN-3-IL) CARBOXAMIDE FOR THE TREATMENT OF PAIN

Country Status (23)

Country Link
US (2) US8143408B2 (en)
EP (1) EP2158198B1 (en)
JP (1) JP2010525056A (en)
KR (1) KR20100015827A (en)
CN (1) CN101687860B (en)
AR (1) AR066266A1 (en)
AU (1) AU2008241610B2 (en)
BR (1) BRPI0810354A2 (en)
CA (1) CA2685141A1 (en)
CL (1) CL2008001170A1 (en)
CO (1) CO6251361A2 (en)
EC (1) ECSP099706A (en)
IL (1) IL201309A0 (en)
MX (1) MX2009011364A (en)
MY (1) MY146662A (en)
NZ (1) NZ581353A (en)
PE (1) PE20090727A1 (en)
RU (1) RU2460730C2 (en)
SA (1) SA08290245B1 (en)
TW (1) TW200848037A (en)
UY (1) UY31046A1 (en)
WO (1) WO2008130320A2 (en)
ZA (1) ZA200907137B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA08290245B1 (en) * 2007-04-23 2012-02-12 استرازينيكا ايه بي Novel n- (8-Heteroaryltetrahydronaphtalene-2-Y1) or N- (5- Heteroarylchromane-3-Y1) Carboxamide Derivatives for the Treatment of Pain
AR074760A1 (en) * 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
US8748623B2 (en) * 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
SG10201500511TA (en) * 2009-10-26 2015-03-30 Signal Pharm Llc Methods Of Synthesis And Purification Of Heteroaryl Compounds
UA103272C2 (en) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS$ 2-AMINO-5,5-DIFLUOR-5,6-DIHYDRO-4H-OXAZINES AS BACE1 AND/OR INHIBITORS OR BACE2
KR20120130104A (en) 2010-02-01 2012-11-28 닛뽕 케미파 가부시키가이샤 Gpr119 agonist
EP2608672B1 (en) 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
WO2012039657A1 (en) * 2010-09-22 2012-03-29 Astrazeneca Ab Novel chromane compound for the treatment of pain disorders
CN102408385B (en) * 2011-06-20 2014-06-18 雅本化学股份有限公司 Preparation method of 2-substituent-2H-1,2,3-triazole derivative
CN102408386B (en) * 2011-07-27 2014-05-07 雅本化学股份有限公司 Preparation method of 2,4-disubstituted-2H-1, 2, 3-triazole derivatives
CN102603659B (en) * 2012-03-01 2014-03-26 雅本化学股份有限公司 1-substituted-4-bromo-1H-1,2,3-triazole-5-carboxylic acid and preparation method thereof
RU2683788C2 (en) * 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Amides of quinoline and quinazoline, useful as a sodium channel modulators
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US9452986B2 (en) * 2014-02-06 2016-09-27 Abbvie Inc. 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use
KR102412146B1 (en) 2015-02-11 2022-06-22 주식회사 아이엔테라퓨틱스 Sodium channel blockers
HRP20201695T1 (en) 2015-11-13 2020-12-25 Daewoong Pharmaceutical Co., Ltd. SODIUM CHANNEL BLOCKERS
CN105541774B (en) * 2016-01-13 2018-06-15 华中师范大学 3,4- dihydrocoumarin class compounds and its preparation method and application
US11485733B2 (en) * 2017-06-30 2022-11-01 Bayer Animal Health Gmbh Azaquinoline derivatives
WO2019144041A1 (en) 2018-01-19 2019-07-25 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
JP7438148B2 (en) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド cardiac sarcomere inhibitor
JP7610985B2 (en) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド Cardiac sarcomere inhibitors
FI3851436T3 (en) 2018-09-10 2024-09-03 Kaken Pharma Co Ltd Novel heteroaromatic amide derivative and medicine containing same
WO2020234103A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft Identification and use of kras inhibitors
CN117083275A (en) 2021-03-04 2023-11-17 赛特凯恩蒂克公司 Cardiac sarcomere inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904361D0 (en) * 1989-12-22 1989-12-22 Astra Ab NEW CHROMAN AND THIOCHROMAN DERIVATIVES
WO1994012493A1 (en) * 1992-11-25 1994-06-09 Sandoz, Ltd. 2,2-dialkyl- and 2,2-dialkyl-3,4-dihydro-3-hydroxy-2h-1-benzopyr ans, their use as pharmaceuticals
JPH0827153A (en) * 1994-07-12 1996-01-30 Nippon Kayaku Co Ltd Azachroman derivative and its use
SE9601110D0 (en) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
GB9713804D0 (en) * 1997-06-30 1997-09-03 Novo Nordisk As Particulate polymeric materials and their use
JPH1135569A (en) 1997-07-22 1999-02-09 Meiji Milk Prod Co Ltd Polyphenol compound and drug containing the same
SE9702799D0 (en) * 1997-07-25 1997-07-25 Astra Ab New compounds
SE9703377D0 (en) * 1997-09-18 1997-09-18 Astra Ab New compounds
SE9703378D0 (en) * 1997-09-18 1997-09-18 Astra Ab New compounds
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
EP1673357A2 (en) * 2003-08-08 2006-06-28 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
JP2008540443A (en) * 2005-05-04 2008-11-20 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrimidines and pyrazines useful as modulators of ion channels
US20090291983A1 (en) * 2006-07-12 2009-11-26 Astrazeneca Ab 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents
SA08290245B1 (en) * 2007-04-23 2012-02-12 استرازينيكا ايه بي Novel n- (8-Heteroaryltetrahydronaphtalene-2-Y1) or N- (5- Heteroarylchromane-3-Y1) Carboxamide Derivatives for the Treatment of Pain

Also Published As

Publication number Publication date
CO6251361A2 (en) 2011-02-21
ZA200907137B (en) 2010-07-28
UY31046A1 (en) 2008-11-28
RU2009138137A (en) 2011-05-27
MY146662A (en) 2012-09-14
US8143408B2 (en) 2012-03-27
EP2158198A4 (en) 2012-01-04
KR20100015827A (en) 2010-02-12
MX2009011364A (en) 2009-11-05
AU2008241610A1 (en) 2008-10-30
RU2460730C2 (en) 2012-09-10
CA2685141A1 (en) 2008-10-30
BRPI0810354A2 (en) 2014-10-21
SA08290245B1 (en) 2012-02-12
JP2010525056A (en) 2010-07-22
US20120238579A1 (en) 2012-09-20
WO2008130320A3 (en) 2008-12-18
NZ581353A (en) 2012-02-24
WO2008130320A2 (en) 2008-10-30
IL201309A0 (en) 2010-05-31
AU2008241610B2 (en) 2011-08-18
PE20090727A1 (en) 2009-07-23
TW200848037A (en) 2008-12-16
AR066266A1 (en) 2009-08-05
CN101687860A (en) 2010-03-31
EP2158198B1 (en) 2013-03-20
CL2008001170A1 (en) 2009-05-22
EP2158198A2 (en) 2010-03-03
CN101687860B (en) 2012-07-04
US20100137322A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
ECSP099706A (en) NEW DERIVATIVES OF N- (8-HETEROARILTETRAHIDRONAFTALEN-2YL) AND N- (5-HETEROARILCROMAN-3-IL) CARBOXAMIDE FOR THE TREATMENT OF PAIN
DOP2010000387A (en) PIRAZOLIC COMPOUNDS 436
UY31063A1 (en) DERIVATIVES OF N- [6-AMINO-5-ARIL-PIRIDIN -2-IL] -CARBOXAMIDE, COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES, METHODS USED IN THE PREPARATION AND APPLICATIONS.
DOP2012000310A (en) MORPHOLINOPIRIMIDINAS AND ITS USE IN THERAPY
CR9954A (en) PIRAZINE DERIVATIVES
NI201100137A (en) SULFONAMIDE DERIVATIVES
UY30610A1 (en) MGLUR5 MODULATORS
BRPI0721905B8 (en) Proteasome inhibitor compound, its pharmaceutical composition and its use
ECSP109903A (en) DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
ECSP077185A (en) PIRIDINE DERIVATIVES
EA201070327A1 (en) CATECHOLAMINE DERIVATIVES AND THEIR DEVICES
UY27740A1 (en) NEW COMPOUNDS
SV2011003802A (en) USEFUL TRIAZOL DERIVATIVES FOR THE TREATMENT OF DISEASES
ECSP088891A (en) BICYCLIC DERIVATIVES AS CETP INHIBITORS
UY31990A (en) NEW DERIVATIVES
MX358961B (en) C7-fluoro substituted tetracycline compounds.
CL2009000445A1 (en) Compounds derived from piperidine 1,4 heterocycle substituted, procedure to prepare these compounds, pharmaceutical composition comprising them and their use for pain therapy and the treatment of diseases such as Alzheimer's, schizophrenia, anxiety and depression.
UY29818A1 (en) NEW AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND THERAPEUTIC USES
UY30356A1 (en) DERIVATIVES OF 3-HALO-N- (2. (4-FLUOROPHENYL) -4-OXOBUTIL) -N-METIL-5- (TRIFLUOROMETIL) BENZAMIDE AND COMPOSITIONS OF THE SAME.
UY28979A1 (en) DERIVATIVES OF 3-CARBOXAMIDE HYDROCLORURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURE AND ITS USE, USED AS SELECTED INHIBITORS OF GSK3
UY29817A1 (en) NEW AZETIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND THERAPEUTIC USE OF THEM.
UY31989A (en) NEW DERIVATIVES
EA200802000A1 (en) PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHIC FORMS
CU20100250A7 (en) PIRAZOLIC COMPOUNDS 436
AR105921A1 (en) THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS OF THESE